The First North American Experience Using Glycosorb Immunoadsorption Columns for Blood Group–Incompatible Kidney Transplantation
Background: Blood group incompatibility (ABOi) is the most common barrier to living donor kidney transplantation. Options for such recipients include kidney paired donation (KPD) or desensitization methodology to reduce blood antibody response. Objective: The objective of this study is to report on...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-10-01
|
Series: | Canadian Journal of Kidney Health and Disease |
Online Access: | https://doi.org/10.1177/2054358120962586 |
id |
doaj-b30e6fb83d0747d09958ab0426cb2469 |
---|---|
record_format |
Article |
spelling |
doaj-b30e6fb83d0747d09958ab0426cb24692020-12-11T18:33:20ZengSAGE PublishingCanadian Journal of Kidney Health and Disease2054-35812020-10-01710.1177/2054358120962586The First North American Experience Using Glycosorb Immunoadsorption Columns for Blood Group–Incompatible Kidney TransplantationKaterina Pavenski0Megan Buchholz1Patti Lou Cheatley2Elizabeth Krok3Monique Anderson4GV Ramesh Prasad5Mohammed Azfar Qureshi6Galo Meliton7Jeffrey Zaltzman8Department of Transfusion Medicine, University of Toronto, ON, CanadaDepartment of Transfusion Medicine, University of Toronto, ON, CanadaDepartment of Transfusion Medicine, University of Toronto, ON, CanadaDepartment of Transfusion Medicine, University of Toronto, ON, CanadaDepartment of Transfusion Medicine, University of Toronto, ON, CanadaDepartment of Medicine, Division of Nephrology and Transplantation, University of Toronto, ON, CanadaSt. Michael’s Hospital, Unity Health Toronto, University of Toronto, ON, CanadaDepartment of Medicine, Division of Nephrology and Transplantation, University of Toronto, ON, CanadaDepartment of Medicine, Division of Nephrology and Transplantation, University of Toronto, ON, CanadaBackground: Blood group incompatibility (ABOi) is the most common barrier to living donor kidney transplantation. Options for such recipients include kidney paired donation (KPD) or desensitization methodology to reduce blood antibody response. Objective: The objective of this study is to report on the first North America experience in ABOi living donor kidney transplantation using Glycosorb ABO immunoadsorption columns. Design: Retrospective observational cohort study. Setting: Renal transplant program at St. Michael’s Hospital, Unity Health Toronto, University of Toronto. Patients: Twenty-six ABOi living donor transplants from August 2011 through February 2020 were undertaken at our center. Measurements: Renal allograft and patient survival postdesensitization for ABOi living donor transplants and isohemagglutinin titer reduction. Methods: Preoperative immunosuppressive regimen consisted of a single dose of Rituximab 375 mg/m 2 IV on day −28; tacrolimus, mycophenolic acid, and prednisone to start on day −7. Immunoadsorption treatments with Glycosorb A or B columns were performed on day −7 through day −1 based on anti-A or anti-B titers on Spectra Optia Apheresis System. Immunosuppression included basiliximab, solumedrol followed by oral prednisone, once-daily tacrolimus, and mycophenolic acid. The mean follow-up was 53 months (3-96 months). Results: A total of 26 individuals underwent an attempt at desensitization of whom 24 patients underwent immediate transplant. One patient had a rebound in titers and subsequently was transplanted from a blood group compatible living donor. A second patient had an unrelated medical issue and desensitization was discontinued. Five-year patient survival was 96% and death censored allograft survival was 92%. Posttransplant anti-A or anti-B titers were monitored daily for the first 7 days posttransplant and every 2 days from days 7 to 14. There were no acute rejections seen in this cohort of transplant recipients. Limitations: As our protocol was first initiated as proof of concept, a few recipients had low initial isohemagglutinin titers. This may have contributed to improved clinical outcomes. Conclusions: ABO column immunoadsorption with specific columns is a safe and effective method for ABOi living donor kidney transplantation, and an option when KPD is less than ideal. Trial not registered as this was a retrospective cohort review.https://doi.org/10.1177/2054358120962586 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Katerina Pavenski Megan Buchholz Patti Lou Cheatley Elizabeth Krok Monique Anderson GV Ramesh Prasad Mohammed Azfar Qureshi Galo Meliton Jeffrey Zaltzman |
spellingShingle |
Katerina Pavenski Megan Buchholz Patti Lou Cheatley Elizabeth Krok Monique Anderson GV Ramesh Prasad Mohammed Azfar Qureshi Galo Meliton Jeffrey Zaltzman The First North American Experience Using Glycosorb Immunoadsorption Columns for Blood Group–Incompatible Kidney Transplantation Canadian Journal of Kidney Health and Disease |
author_facet |
Katerina Pavenski Megan Buchholz Patti Lou Cheatley Elizabeth Krok Monique Anderson GV Ramesh Prasad Mohammed Azfar Qureshi Galo Meliton Jeffrey Zaltzman |
author_sort |
Katerina Pavenski |
title |
The First North American Experience Using Glycosorb Immunoadsorption Columns for Blood Group–Incompatible Kidney Transplantation |
title_short |
The First North American Experience Using Glycosorb Immunoadsorption Columns for Blood Group–Incompatible Kidney Transplantation |
title_full |
The First North American Experience Using Glycosorb Immunoadsorption Columns for Blood Group–Incompatible Kidney Transplantation |
title_fullStr |
The First North American Experience Using Glycosorb Immunoadsorption Columns for Blood Group–Incompatible Kidney Transplantation |
title_full_unstemmed |
The First North American Experience Using Glycosorb Immunoadsorption Columns for Blood Group–Incompatible Kidney Transplantation |
title_sort |
first north american experience using glycosorb immunoadsorption columns for blood group–incompatible kidney transplantation |
publisher |
SAGE Publishing |
series |
Canadian Journal of Kidney Health and Disease |
issn |
2054-3581 |
publishDate |
2020-10-01 |
description |
Background: Blood group incompatibility (ABOi) is the most common barrier to living donor kidney transplantation. Options for such recipients include kidney paired donation (KPD) or desensitization methodology to reduce blood antibody response. Objective: The objective of this study is to report on the first North America experience in ABOi living donor kidney transplantation using Glycosorb ABO immunoadsorption columns. Design: Retrospective observational cohort study. Setting: Renal transplant program at St. Michael’s Hospital, Unity Health Toronto, University of Toronto. Patients: Twenty-six ABOi living donor transplants from August 2011 through February 2020 were undertaken at our center. Measurements: Renal allograft and patient survival postdesensitization for ABOi living donor transplants and isohemagglutinin titer reduction. Methods: Preoperative immunosuppressive regimen consisted of a single dose of Rituximab 375 mg/m 2 IV on day −28; tacrolimus, mycophenolic acid, and prednisone to start on day −7. Immunoadsorption treatments with Glycosorb A or B columns were performed on day −7 through day −1 based on anti-A or anti-B titers on Spectra Optia Apheresis System. Immunosuppression included basiliximab, solumedrol followed by oral prednisone, once-daily tacrolimus, and mycophenolic acid. The mean follow-up was 53 months (3-96 months). Results: A total of 26 individuals underwent an attempt at desensitization of whom 24 patients underwent immediate transplant. One patient had a rebound in titers and subsequently was transplanted from a blood group compatible living donor. A second patient had an unrelated medical issue and desensitization was discontinued. Five-year patient survival was 96% and death censored allograft survival was 92%. Posttransplant anti-A or anti-B titers were monitored daily for the first 7 days posttransplant and every 2 days from days 7 to 14. There were no acute rejections seen in this cohort of transplant recipients. Limitations: As our protocol was first initiated as proof of concept, a few recipients had low initial isohemagglutinin titers. This may have contributed to improved clinical outcomes. Conclusions: ABO column immunoadsorption with specific columns is a safe and effective method for ABOi living donor kidney transplantation, and an option when KPD is less than ideal. Trial not registered as this was a retrospective cohort review. |
url |
https://doi.org/10.1177/2054358120962586 |
work_keys_str_mv |
AT katerinapavenski thefirstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT meganbuchholz thefirstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT pattiloucheatley thefirstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT elizabethkrok thefirstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT moniqueanderson thefirstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT gvrameshprasad thefirstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT mohammedazfarqureshi thefirstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT galomeliton thefirstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT jeffreyzaltzman thefirstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT katerinapavenski firstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT meganbuchholz firstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT pattiloucheatley firstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT elizabethkrok firstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT moniqueanderson firstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT gvrameshprasad firstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT mohammedazfarqureshi firstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT galomeliton firstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation AT jeffreyzaltzman firstnorthamericanexperienceusingglycosorbimmunoadsorptioncolumnsforbloodgroupincompatiblekidneytransplantation |
_version_ |
1724386156115656704 |